期刊文献+

吉非替尼治疗34例晚期非小细胞肺癌的临床观察 被引量:2

Clinical observation of Gefitinib for 34 patients with advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:探讨晚期非小细胞肺癌(NSCLC)患者应用吉非替尼治疗的效果及毒副作用。方法:34例经放化疗失败的非小细胞肺癌晚期患者,均发生远处转移。口服吉非替尼250mg/次,每天1次,服药中位时间为4个月。结果:34例晚期NSCLC患者,无一例完全缓解(CR),19例部分缓解(PR),10例稳定(SD),5例进展(PD),全组有效率(CR+PR)为55.9%,临床获益率(CR+PR+SD)为85.3%。中位生存期5.6个月,1年生存率为47.1%(16/34)。结论:吉非替尼治疗晚期NSCLC的疗效较好,毒副作用较轻,可以耐受。 Objective:To explore the efficacy and toxicity of Gefitinib for the patients with advanced non-small cell lung cancer(NSCLC).Methods:34 patients with advanced NSCLC were unsuitable for chemoradio therapy.Gefitinib was administered orally at 250 mg,once a day until cancer progressed or serve toxicities occurred.The median time for administered of Gefitinib was 4 months.Results:Among the 34 NSCLC,no complete response(CR) and 19 partial response(PR),the objective response rate(CR+PR) was 55.9%,and the disease control rate(CR+PR+SD) was 85.3%.The median survival time was 5.6 months,and one year survival rate was 47.1%(16/34).Conclusion:Gefitinib in the treatment of patients with advanced NSCLC has better efficacy and well-tolerated toxicity.
出处 《中国医药导报》 CAS 2010年第18期72-72,74,共2页 China Medical Herald
关键词 非小细胞肺癌 吉非替尼 靶向治疗 表皮生长因子受体 Non-small cell lung cancer(NSCLC) Gefitinib Target therapy Epidermal growth factor receptor
  • 相关文献

参考文献6

二级参考文献35

  • 1潘振奎,张力,张星,王欣,李宁,徐菲,常建华,管忠震.中国非小细胞肺癌患者表皮生长因子受体突变的研究[J].癌症,2005,24(8):919-923. 被引量:44
  • 2Scagliotti GV, Parikh P, yon Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non- small-cell lung cancer [ J]. J Clin Oneol, 2008, 26:3543 -3551.
  • 3Han JY, Lee DH, Song JE, et al. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer[J]. Cancer, 2008,113:388 - 395.
  • 4Mencoboni M, Bergaglio M, Serra M, et al. Maintenance therapy with gefitinib after first - line chemotherapy in patients affected by advanced non - small cell lung cancer [ J ]. Anticancer Res, 2007,27:4425 -4429.
  • 5Kelly K, Chansky K, Gaspar LE, et al. Phase Ⅲ trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage Ⅲ non - small - cell lung cancer: SWOG S0023 [ J ]. J Clin Oncol, 2008,26:2450 - 2456.
  • 6Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase Ⅲ trial[J]. Lung Cancer,2006, 52:155 - 163.
  • 7Fidias PM, Dakhil SR, Lyss AP, et al. Phase Ⅲ Study of Immediate Compared With Delayed Docetaxel After Front - Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non - Small -Cell Lung Cancer[J]. J Clin Oncol, 2009,27 (4):591 -598.
  • 8Xu JM, Han Y, Li YM, et at. Phase Ⅱ trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non - small - cell lung cancer [J]. BMC Cancer, 2006,16:288.
  • 9Ng R, Loreto M, Lee R, et al. Brief report : retrospective review of efficacy of erlotinib or gefitinib compared to doeetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy[ J ]. Lung Cancer, 2008,61:262 - 265.
  • 10Giaceone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 1 [ J]. J Clin Oncol, 2004,22 : 777 -784.

共引文献171

同被引文献23

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部